Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis

What Was Tested

The trial (not phased) is built around Teriparatide for osteoporosis and bone density.

BTMs may show a response to medication within just 3 to 6 months.

It had two arms (groups): Anabolic Therapy Group (experimental) and Antiresorptive Therapy Group (active comparator).

The registry classes the interventions as drug.

More on the Plan

The study is motivated by the high prevalence of osteoporosis in this demographic in Pakistan and the limitations of the current gold standard, BMD measured by DEXA scan, which reflects changes in bone strength at a delayed rate.

BTMs, being biochemical indicators of bone formation and resorption, offer a dynamic and rapid assessment of bone metabolic activity, potentially providing an early measure of treatment response within months rather than years.

The primary outcomes include the comparative change in specific BTMs (BsALP, TRACP-5b, and Sclerostin) at three and six months, and the change in BMD at six months.

Secondary outcomes will assess the correlation between BTM and BMD changes, as well as fracture incidence and quality of life.

Who Took Part

40 actual participants took part.

It was open to people of any sex aged from 50 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Postmenopausal women (at least one year since last menstrual cycle). Age greater than 50 years. Diagnosis of primary osteoporosis. Currently not on any anti-osteoporosis medications. Not taking Calcium or Vitamin D supplements.

The full record lists 6 inclusion and 5 exclusion criteria; among the exclusions: women with multiple vertebral fractures or severe lumbar degenerative changes; use of hormone/estrogen therapy, calcitonin, oral bisphosphonates, iv ibandronate, iv zoledronic acid, denosumab, or teriparatide within the past 18 months; use of corticosteroids (short or long-term).

How the Study Was Run

Design: randomized, parallel-group and double-blind.

The osteoporosis and bone density participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Groups ran in parallel: each of the osteoporosis and bone density participants stayed in one arm throughout.

As a double-blind Teriparatide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2025-10-01 with completion listed for 2026-03-25.

It ran at 1 site in Pakistan.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Change in Bone Turnover Markers (BTMs) (time frame: Baseline, 3 months, and 6 months). Change in Bone Mineral Density (BMD) (time frame: Baseline and 6 months).

It also tracked 1 secondary outcome, for example Incidence of New Fractures.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Teriparatide in 40 people with osteoporosis and bone density.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Teriparatide compound page, Osteoporosis and bone density research.